RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:596753

VEXAS syndrome

low confidenceDisorder

Publications

1,126

Trials

5

Interventional, condition-specific

Researchers

1,473

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare autoinflammatory syndrome characterized by adult onset of rheumatologic manifestations such as recurrent fever, skin and pulmonary inflammation, ear and nose chondritis, vasculitis, deep vein thrombosis, and arthralgia. Laboratory examination reveals hematologic abnormalities including macrocytic anemia and thrombocytopenia, as well as elevated inflammatory markers. Bone marrow biopsy shows hypercellularity and signs of bone marrow . The disease primarily occurs in males and is caused by somatic mutations on chromosome Xp11.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

VEXAS · VEXAS syndrome, somatic · vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,126 matched papers (1,120 in last 10 years) Source

  3. Phenotype characterisedPresent

    23 HPO annotations (e.g. Neutrophilic infiltration of the skin; Skin plaque; Deep venous thrombosis) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    1 EMA designation (none yet with FDA orphan-indication approval) — e.g. Momelotinib dihydrochloride monohydrate Source

  6. Interventional trialPresent

    5 matched on ClinicalTrials.gov (5 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

23

Associated phenotypes · MONDO:0026777

  • Neutrophilic infiltration of the skin
  • Skin plaque
  • Deep venous thrombosis
  • Thrombocytopenia
  • Myelodysplasia

Showing 5 of 23 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · no FDA orphan-indication approval yet

  • EMA Momelotinib dihydrochloride monohydrateTreatment of VEXAS syndrome · 20/04/2026 · PositiveEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

7

Drugs / clinical candidates · MONDO_0026777

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,126

1,126 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,126 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,120 in the last 10 years · low confidence

Phrase hits: 1,126 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,473

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Beck DB14 papers · 2026

    Center for Human Genetics and Genomics, NYU School of Medicine, New York, NY 10016, USA.

    Papers in Europe PMC
  2. 02
    Georgin-Lavialle S12 papers · 2026

    Department of Internal Medicine, CEREMAIA, Sorbonne Université, Hôpital Tenon, Assistance Publique-Hôpitaux Paris, Paris, France.

    Papers in Europe PMC
  3. 03
    Mekinian A12 papers · 2026

    Sorbonne Université, Service de Médecine Interne, AP-HP, Hôpital Saint-Antoine, CEREMAIAA, 75012 Paris, France.

    Papers in Europe PMC
  4. 04
    Campochiaro C11 papers · 2026

    Vita-Salute San Raffaele University, Milan, Italy.

    Papers in Europe PMC
  5. 05
    Kosmider O11 papers · 2026

    Department of Laboratory Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.

    Papers in Europe PMC
  6. 06
    Terrier B11 papers · 2026

    Department of Internal Medicine, Université Paris-Cité, Hôpital Cochin, Assistance Publique-Hôpitaux Paris, Paris, France.

    Papers in Europe PMC
  7. 07
    Ferrada MA10 papers · 2026

    Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

    Papers in Europe PMC
  8. 08
    Grayson PC10 papers · 2026

    National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA.

    Papers in Europe PMC
  9. 09
    Gurnari C10 papers · 2026

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.

    Papers in Europe PMC
  10. 10
    Kirino Y10 papers · 2026

    Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: kirino@yokohama-cu.ac.jp.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

5

interventional trials for this specific condition

5 interventional trials matched this specific condition name; 5 currently recruiting in our sample.

Data as of 11 September 2026

5 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 89.2th percentile).

low confidence · 89.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

5 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 56 · after dedupe 55 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 55 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (55)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for VEXAS syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("VEXAS syndrome" OR "VEXAS" OR "VEXAS syndrome, somatic" OR "vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome") OR ("VEXAS-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"VEXAS syndrome" OR "VEXAS" OR "VEXAS syndrome, somatic" OR "vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 5 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1126) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T18:51:20.222Z